MicroRNAs in cancer biology and therapy: Current status and perspectives

Genes and Diseases

Volumn 1, Issue 1, 2014, Pages 53-63

  Price, Colles ^a   Chen, Jianjun ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

Author keywords

Cancer biology; Drug therapy; MiRNAs; Nanoparticles; Oncogene; Tumor suppressor

Indexed keywords

MICRORNA;

BIOLOGY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; GENE CONTROL; GENETIC TRANSCRIPTION; HUMAN; ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

EID: 84939771193     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2014.06.004     Document Type: Review

References (169)

1. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell Dec 3 1993, 75(5):843-854.
2. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell Dec 3 1993, 75(5):855-862.
3. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science Oct 26 2001, 294(5543):853-858.
4. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science Oct 26 2001, 294(5543):862-864.
5. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science Oct 26 2001, 294(5543):858-862.
6. Wahid F., Shehzad A., Khan T., Kim Y.Y. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2010, 1803(11):1231-1243.
7. Carthew R.W., Sontheimer E.J. Origins and mechanisms of miRNAs and siRNAs. Cell 20 Feb 2009, 136(4):642-655.
8. Alemán L.M., Doench J., Sharp P.A. Comparison of siRNA-induced off-target RNA and protein effects. RNA March 1 2007.
9. Abelson J.F., Kwan K.Y., O'Roak B.J., et al. Sequence variants in SLITRK1 are associated with Tourette's Syndrome. Science October 14, 2005, 310(5746):317-320.
10. Yu Z., Li Z., Jolicoeur N., et al. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 2007, 35(13):4535-4541.
11. Moss E.G., Lee R.C., Ambros V. The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell Mar 7 1997, 88(5):637-646.
12. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA Nov 26 2002, 99(24):15524-15529.
13. McManus M.T. MicroRNAs and cancer. Semin Cancer Biol Aug 2003, 13(4):253-258.
14. Michael M.Z., OC S.M., van Holst Pellekaan N.G., Young G.P., James R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res Oct 2003, 1(12):882-891.
15. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature Jun 9 2005, 435(7043):834-838.
16. He L., Thomson J.M., Hemann M.T., et al. A microRNA polycistron as a potential human oncogene. Nature Jun 9 2005, 435(7043):828-833.
17. O'Donnell K., Wentzel E., Zeller K., Dang C., Mendell J. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
18. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell Mar 4 2011, 144(5):646-674.
19. Garzon R., Liu S., Fabbri M., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood Jun 18 2009, 113(25):6411-6418.
20. Liu S., Wu L.C., Pang J., et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell Apr 13 2010, 17(4):333-347.
21. He L., He X., Lim L.P., et al. A microRNA component of the p53 tumour suppressor network. Nature Jun 28 2007, 447(7148):1130-1134.
22. Okada N., Lin C.P., Ribeiro M.C., et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev Mar 1 2014, 28(5):438-450.
23. Tavazoie S.F., Alarcon C., Oskarsson T., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature Jan 10 2008, 451(7175):147-152.
24. Zhang J., Du Y.Y., Lin Y.F., et al. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun Dec 5 2008, 377(1):136-140.
25. Liu B., Peng X.C., Zheng X.L., Wang J., Qin Y.W. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines invitro and invivo. Lung Cancer Feb 13 2009.
26. Crawford M., Brawner E., Batte K., et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun Sep 5 2008, 373(4):607-612.
27. Guo C., Sah J.F., Beard L., Willson J.K., Markowitz S.D., Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer Nov 2008, 47(11):939-946.
28. Jiang X., Huang H., Li Z., et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell Oct 16 2012, 22(4):524-535.
29. Gasparini P., Lovat F., Fassan M., et al. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci USA March 10 2014.
30. Rokah O.H., Granot G., Ovcharenko A., et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS ONE 2012, 7(4):e35501.
31. Li Z., Huang H., Li Y., et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood Mar 8 2012, 119(10):2314-2324.
32. Schwind S., Maharry K., Radmacher M.D., et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol Dec 20 2010, 28(36):5257-5264.
33. Ward A., Balwierz A., Zhang J.D., et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene Feb 28 2013, 32(9):1173-1182.
34. Romano G., Acunzo M., Garofalo M., et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA Oct 9 2012, 109(41):16570-16575.
35. Li Z., Cao Y., Jie Z., et al. miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett Oct 1 2012, 323(1):41-47.
36. Jiang X., Huang H., Li Z., et al. miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proc Natl Acad Sci USA Nov 20 2012, 109(47):19397-19402.
37. Chen P., Price C., Li Z., et al. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci USA July 9 2013, 110(28):11511-11516.
38. Mi S., Li Z., Chen P., et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proc Natl Acad Sci USA Feb 23 2010, 107(8):3710-3715.
39. Li Z., Luo R.T., Mi S., et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res Feb 1 2009, 69(3):1109-1116.
40. Wong P., Iwasaki M., Somervaille T.C., et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res May 1 2010, 70(9):3833-3842.
41. Mandal C.C., Ghosh-Choudhury T., Dey N., Choudhury G.G., Ghosh-Choudhury N. miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. Carcinogenesis Oct 2012, 33(10):1897-1908.
42. Acunzo M., Romano G., Palmieri D., et al. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci USA May 21, 2013, 110(21):8573-8578.
43. Moch H., Lukamowicz-Rajska M. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation. Cancer Discov January 1, 2014, 4(1):22-24.
44. Li Z., Lu J., Sun M., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA Oct 7 2008, 105(40):15535-15540.
45. Wang Y., Yu Y., Tsuyada A., et al. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene Mar 24 2011, 30(12):1470-1480.
46. Wang B., Hsu S.H., Majumder S., et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene Mar 25 2010, 29(12):1787-1797.
47. Wei Z., Cui L., Mei Z., Liu M., Zhang D. miR-181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway. FEBS Lett May 2 2014, 588(9):1773-1779.
48. Tsai K.W., Liao Y.L., Wu C.W., et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer Apr 2012, 51(4):394-401.
49. Li Z., Huang H., Chen P., et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 2012, 2:688.
50. Zhou H., Xiao B., Zhou F., et al. MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients. Biomarkers: biochemical indicators of exposure, response, and susceptibility to chemicals Mar 2012, 17(2):104-110.
51. Pillai R.S., Bhattacharyya S.N., Artus C.G., et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science Sep 2 2005, 309(5740):1573-1576.
52. Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev Mar 1 2006, 20(5):515-524.
53. Bagga S., Bracht J., Hunter S., et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell Aug 26 2005, 122(4):553-563.
54. Lim L.P., Lau N.C., Garrett-Engele P., et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature Feb 17 2005, 433(7027):769-773.
55. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell Jan 23 2004, 116(2):281-297.
56. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell Jan 23 2009, 136(2):215-233.
57. Cullen B.R. Transcription and processing of human microRNA precursors. Mol Cell Dec 22 2004, 16(6):861-865.
58. Ambros V. The functions of animal microRNAs. Nature Sep 16 2004, 431(7006):350-355.
59. Krutzfeldt J., Rajewsky N., Braich R., et al. Silencing of microRNAs invivo with 'antagomirs'. Nature Dec 1 2005, 438(7068):685-689.
60. Jackson A.L., Bartz S.R., Schelter J., et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol Jun 2003, 21(6):635-637.
61. Sood P., Krek A., Zavolan M., Macino G., Rajewsky N. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci USA Feb 13 2006.
62. He H., Jazdzewski K., Li W., et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA Dec 27 2005, 102(52):19075-19080.
63. Farh K.K., Grimson A., Jan C., et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science Dec 16 2005, 310(5755):1817-1821.
64. Humphreys D.T., Westman B.J., Martin D.I., Preiss T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci USA Nov 22 2005, 102(47):16961-16966.
65. Kiriakidou M., Tan G.S., Lamprinaki S., De Planell-Saguer M., Nelson P.T., Mourelatos Z. An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell Jun 15 2007, 129(6):1141-1151.
66. Mathonnet G., Fabian M.R., Svitkin Y.V., et al. MicroRNA inhibition of translation initiation invitro by targeting the cap-binding complex eIF4F. Science Sep 21 2007, 317(5845):1764-1767.
67. Thermann R., Hentze M.W. Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. Nature Jun 14 2007, 447(7146):875-878.
68. Ding X.C., Grosshans H. Repression of C. elegans microRNA targets at the initiation level of translation requires GW182 proteins. EMBO J Feb 4 2009, 28(3):213-222.
69. Petersen C.P., Bordeleau M.E., Pelletier J., Sharp P.A. Short RNAs repress translation after initiation in mammalian cells. Mol Cell Feb 17 2006, 21(4):533-542.
70. Eulalio A., Huntzinger E., Izaurralde E. GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay. Nat Struct Mol Biol Apr 2008, 15(4):346-353.
71. Behm-Ansmant I., Rehwinkel J., Doerks T., Stark A., Bork P., Izaurralde E. mRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev Jul 15 2006, 20(14):1885-1898.
72. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature Sep 4 2008, 455(7209):64-71.
73. Giraldez A.J., M Y., Rihel J., Grocock R.J., Van Dongen S., Inoue K., Enright A.J., Schier A.F. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science Apr 2006, 312(5770):75-79.
74. Wu L., Fan J., Belasco J.G. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA Mar 14 2006, 103(11):4034-4039.
75. Wakiyama M., Takimoto K., Ohara O., Yokoyama S. Let-7 microRNA-mediated mRNA deadenylation and translational repression in a mammalian cell-free system. Genes Dev Aug 1 2007, 21(15):1857-1862.
76. Seggerson K., Tang L., Moss E.G. Two genetic circuits repress the Caenorhabditis elegans heterochronic gene lin-28 after translation initiation. Dev Biol Mar 15 2002, 243(2):215-225.
77. Maroney P.A., Yu Y., Fisher J., Nilsen T.W. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat Struct Mol Biol Dec 2006, 13(12):1102-1107.
78. Siomi H., Siomi M.C. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell May 14 2010, 38(3):323-332.
79. Pekarsky Y., S U., Cimmino A., Palamarchuk A., Efanov A., Maximov V., Volinia S., Alder H., Liu C.G., Rassenti L., Calin G.A., Hagan J.P., Kipps T., Croce C.M. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006, 66(24):11590-11593.
80. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell Aug 27 2010, 39(4):493-506.
81. Mavrakis K.J., Van Der Meulen J., Wolfe A.L., et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet Jul 2011, 43(7):673-678.
82. Mavrakis K.J., Leslie C.S., Wendel H.G. Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle Sep 1 2011, 10(17):2845-2849.
83. Garzon R., Calin G.A., Croce C.M. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
84. Nana-Sinkam S.P., Croce C.M. Non-coding RNAs in cancer initiation and progression and as novel biomarkers. Mol Oncol Dec 2011, 5(6):483-491.
85. Visone R., Veronese A., Balatti V., Croce C.M. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget Feb 2012, 3(2):195-202.
86. Mu P., Han Y.C., Betel D., et al. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev Dec 15 2009, 23(24):2806-2811.
87. Olive V., Bennett M.J., Walker J.C., et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev Dec 15 2009, 23(24):2839-2849.
88. Shi M., Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev Jan 24 2009.
89. Hossain A., Kuo M.T., Saunders G.F. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol Nov 2006, 26(21):8191-8201.
90. Yu Z., Wang C., Wang M., et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol Aug 11 2008, 182(3):509-517.
91. Yu Z., Willmarth N.E., Zhou J., et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA May 4 2010, 107(18):8231-8236.
92. Guil S., Caceres J.F. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat Struct Mol Biol Jul 2007, 14(7):591-596.
93. Eiring A.M., Harb J.G., Neviani P., et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell Mar 5 2010, 140(5):652-665.
94. Garofalo M., Romano G., Di Leva G., et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med Jan 2012, 18(1):74-82.
95. Hu S., Dong T.S., Dalal S.R., et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One 2011, 6(1):e16221.
96. Humphreys K.J., Cobiac L., Le Leu R.K., Van der Hoek M.B., Michael M.Z. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol Carcinog Jun 2013, 52(6):459-474.
97. Watashi K., Yeung M.L., Starost M.F., Hosmane R.S., Jeang K.T. Identification of small molecules that suppress microRNA function and reverse tumorigenesis. J Biol Chem Aug 6 2010, 285(32):24707-24716.
98. Cheng C.J., Slack F.J. The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J May-Jun 2012, 18(3):232-237.
99. Lennox K.A., Behlke M.A. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther Dec 2011, 18(12):1111-1120.
100. Elmen J., Lindow M., Schutz S., et al. LNA-mediated microRNA silencing in non-human primates. Nature Apr 17 2008, 452(7189):896-899.
101. Stenvang J., Silahtaroglu A.N., Lindow M., Elmen J., Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol Apr 2008, 18(2):89-102.
102. Lu Y., Xiao J., Lin H., et al. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res Jan 9 2009.
103. Wolfrum C., Shi S., Jayaprakash K.N., et al. Mechanisms and optimization of invivo delivery of lipophilic siRNAs. Nat Biotechnol Oct 2007, 25(10):1149-1157.
104. Stenvang J., Petri A., Lindow M., Obad S., Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012, 3(1):1.
105. Sheridan C. Gene therapy finds its niche. Nat Biotechnol Feb 2011, 29(2):121-128.
106. Huang X., Schwind S., Yu B., et al. Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res May 1 2013, 19(9):2355-2367.
107. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet May 2003, 4(5):346-358.
108. Haraguchi T., Ozaki Y., Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res Apr 2009, 37(6):e43.
109. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target Aug-Sep 2007, 15(7-8):457-464.
110. Su J., Baigude H., McCarroll J., Rana T.M. Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res Mar 2011, 39(6):e38.
111. Babar I.A., Cheng C.J., Booth C.J., et al. Nanoparticle-based therapy in an invivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA June 26 2012, 109(26):E1695-E1704.
112. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med May 1 2008, 358(18):1919-1928.
113. Marcucci G., Maharry K., Radmacher M.D., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol Nov 1 2008, 26(31):5078-5087.
114. Yang C., Wang C., Chen X., et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer Jan 1 2013, 132(1):116-127.
115. Leung A.K., Sharp P.A. microRNAs: a safeguard against turmoil?. Cell Aug 24 2007, 130(4):581-585.
116. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science Dec 21 2007, 318(5858):1931-1934.
117. Volinia S., Calin G.A., Liu C.G., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA Feb 14 2006, 103(7):2257-2261.
118. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell Jun 13 2003, 113(6):673-676.
119. McManus M.T., Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet Oct 2002, 3(10):737-747.
120. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet Oct 2009, 10(10):704-714.
121. Fabbri M., Croce C.M. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol Jul 2011, 18(4):266-272.
122. Chen X., Ba Y., Ma L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res Oct 2008, 18(10):997-1006.
123. Gilad S., Meiri E., Yogev Y., et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3(9):e3148.
124. Lawrie C.H., Gal S., Dunlop H.M., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol May 2008, 141(5):672-675.
125. Mitchell P.S., Parkin R.K., Kroh E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA Jul 29 2008, 105(30):10513-10518.
126. Wang K., Zhang S., Marzolf B., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA Mar 17 2009, 106(11):4402-4407.
127. Lodes M.J., Caraballo M., Suciu D., Munro S., Kumar A., Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4(7):e6229.
128. Brase J.C., Johannes M., Schlomm T., et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer Feb 1 2011, 128(3):608-616.
129. Tanaka M., Oikawa K., Takanashi M., et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009, 4(5):e5532.
130. Wang J., Chen J., Chang P., et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Philadelphia, Pa.) Sep 2009, 2(9):807-813.
131. Ho A.S., Huang X., Cao H., et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol Apr 2010, 3(2):109-113.
132. Kong X., Du Y., Wang G., et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci Feb 2011, 56(2):602-609.
133. Li A., Omura N., Hong S.M., et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res Jul 1 2010, 70(13):5226-5237.
134. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol Jan 2009, 112(1):55-59.
135. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Kerin M.J. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009, 2009:950201.
136. Zhu W., Qin W., Atasoy U., Sauter E.R. Circulating microRNAs in breast cancer and healthy subjects. BMC Research Notes 2009, 2:89.
137. Roth C., Rack B., Muller V., Janni W., Pantel K., Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010, 12(6):R90.
138. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem Jan 2011, 57(1):84-91.
139. Ng E.K., Chong W.W., Jin H., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut Oct 2009, 58(10):1375-1381.
140. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer Jul 1 2010, 127(1):118-126.
141. Tsujiura M., Ichikawa D., Komatsu S., et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer Mar 30 2010, 102(7):1174-1179.
142. Liu R., Zhang C., Hu Z., et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer Mar 2011, 47(5):784-791.
143. Zhang C., Wang C., Chen X., et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem Dec 2010, 56(12):1871-1879.
144. Komatsu S., Ichikawa D., Takeshita H., et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer Jun 28 2011, 105(1):104-111.
145. Hu Z., Chen X., Zhao Y., et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol Apr 1 2010, 28(10):1721-1726.
146. Foss K.M., Sima C., Ugolini D., Neri M., Allen K.E., Weiss G.J. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol: Official Publication of the International Association for the Study of Lung Cancer Mar 2011, 6(3):482-488.
147. Liu X.G., Zhu W.Y., Huang Y.Y., et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol Jun 2012, 29(2):618-626.
148. Wei J., Gao W., Zhu C.J., et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer Jun 2011, 30(6):407-414.
149. Weiland M., Gao X.H., Zhou L., Mi Q.S. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol Jun 2012, 9(6):850-859.
150. Wulfken L.M., Moritz R., Ohlmann C., et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 2011, 6(9):e25787.
151. van Schooneveld E., Wouters M.C., Van der Auwera I., et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res 2012, 14(1):R34.
152. Yang M., Chen J., Su F., et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 2011, 10:117.
153. LaConti J.J., Shivapurkar N., Preet A., et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 2011, 6(6):e20687.
154. Wong C.M., Wong C.C., Lee J.M., Fan D.N., Au S.L., Ng I.O. Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology May 2012, 55(5):1453-1461.
155. Kim D.J., Linnstaedt S., Palma J., et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn Jan 2012, 14(1):71-80.
156. Wang T., Lv M., Shen S., et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS One 2012, 7(8):e43268.
157. Gao W., Li J.Z., Ho W.K., Chan J.Y., Wong T.S. Biomarkers for use in monitoring responses of nasopharyngeal carcinoma cells to ionizing radiation. Sensors (Basel, Switzerland) 2012, 12(7):8832-8846.
158. Akiyoshi S., Fukagawa T., Ueo H., et al. Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer Oct 9 2012, 107(8):1345-1353.
159. Jones C.I., Zabolotskaya M.V., King A.J., et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer Dec 4 2012, 107(12):1987-1996.
160. Wang Z., Han J., Cui Y., Fan K., Zhou X. Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy. Med Hypotheses Jul 2013, 81(1):41-43.
161. Wong K.F., Xu Z., Chen J., Lee N.P., Luk J.M. Circulating markers for prognosis of hepatocellular carcinoma. Expert Opin Med Diagn Jul 2013, 7(4):319-329.
162. Wong T.S., Liu X.B., Wong B.Y., Ng R.W., Yuen A.P., Wei W.I. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res May 1 2008, 14(9):2588-2592.
163. Lin S.C., Liu C.J., Lin J.A., Chiang W.F., Hung P.S., Chang K.W. miR-24 up-regulation in oral carcinoma: positive association from clinical and invitro analysis. Oral Oncol Mar 2010, 46(3):204-208.
164. Liu C.J., Kao S.Y., Tu H.F., Tsai M.M., Chang K.W., Lin S.C. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis May 2010, 16(4):360-364.
165. Fabbri M., Paone A., Calore F., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA Jul 31 2012, 109(31):E2110-2116.
166. Lund J.M., Alexopoulou L., Sato A., et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA Apr 13 2004, 101(15):5598-5603.
167. Heil F., Hemmi H., Hochrein H., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science Mar 5 2004, 303(5663):1526-1529.
168. Fabbri M. TLRs as miRNA receptors. Cancer Res Dec 15 2012, 72(24):6333-6337.
169. Fabbri M., Paone A., Calore F., Galli R., Croce C.M. A new role for microRNAs, as ligands of Toll-like receptors. RNA Biol Feb 2013, 10(2):169-174.